- Home
- NTSK vs TVTX Comparison
NTSK vs TVTX Comparison
Compare NTSK & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTSK | TVTX |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United States |
| Employees | 3281 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 2.8B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | NTSK | TVTX |
|---|---|---|
| Price | $9.34 | $42.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 11 |
| Target Price | $18.53 | ★ $35.10 |
| AVG Volume (30 Days) | ★ 4.4M | 1.4M |
| Earning Date | 03-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.76 | $43.88 |
| Revenue Next Year | $22.02 | $33.16 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.67 | $13.88 |
| 52 Week High | $24.98 | $42.13 |
Technical Indicators
Market Signals| Indicator | NTSK | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.06 | 77.59 |
| Support Level | $8.97 | $32.62 |
| Resistance Level | $12.82 | N/A |
| Average True Range (ATR) | 0.66 | 1.98 |
| MACD | 0.18 | 0.99 |
| Stochastic Oscillator | 68.87 | 100.00 |
Price Performance
Historical ComparisonAbout NTSK Netskope Inc.
Netskope Inc is redefining the security and networking of cloud and AI. The company has formed a cloud-native platform that offers converged security, networking services, and analytics technology stack to enable fast and secure AI, cloud, and web access at the edge.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.